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Editorial  
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      ABSTRACT 
The incidence of breast cancer increases with age. Despite this, most re-
search in this field is aimed at the younger patient. Preliminary studies have 
shown that older women with breast cancer have distinct biological features 
compared to their younger counterparts. In addition, the focus of treatment 
of older women may not simply be curative but may be a trade-off between 
risks of treatment and impact on independence and quality of life. The Not-
tingham research programme is a unique programme dedicated to primary 
breast cancer in older women. There are two arms of the research pro-
gramme 1) determining the biological differences of breast cancer in this co-
hort 2) exploring the use of geriatric assessment to understand the complex 
needs and factors contributing to treatment decision making in this group 
of patients. The overall aim of the research programme is to optimise both 
the biological and geriatric assessment of older women with primary breast 
cancer, to provide personalised data at diagnosis, on likely survival and 
quality of life outcomes following breast cancer treatment. This article will 
outline why this research programme is important, what it has achieved so 
far and future aspirations.  
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INTRODUCTION 
Importance of Breast cancer in older women 
Breast cancer is the most common cancer in women worldwide (1) and age is the biggest risk factor for devel-
opment of breast cancer; risk increasing proportionally with age (2). In 2018, the number of new breast cancers 
diagnosed worldwide was approximately 2 million (3) with around 25% of cases in patients 70 years (4). Due 
to ageing of the world’s population, it is expected that the number of older women living with breast cancer 
will double by 2040 to nearly 1 million cases in patients 70 worldwide per year (1, 5). 
The ageing of the world’s population is the result of the continued decline in fertility rates and increased life 
expectancy (6). This demographic change has resulted in increasing proportions of older persons. In 2019, 
approximately 9% of the global population were 65 years of age (7) and this is expected to double by 2050 
(8). The crisis of our ageing population has been well documented (9, 10); the burden on health service re-
sources in terms of financial and service provision will be unprecedented. Breast cancer in older women will 
have a significant impact on this. 
 
Differences between breast cancer in older compared to younger women 
Existing data suggests that the biology of breast cancer in older women is different compared to their younger 
counterparts (11) and this may impact treatment decision making, alongside conventional factors, patient 
preference and discussion with the multidisciplinary healthcare team. For example, ER-positivity of breast 
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cancer increases with increasing age (12), thereby making primary endocrine therapy (PET) a potential pri-
mary treatment option in older women. A number of other biomarkers have been identified outside of those 
routinely measured, which could potentially have predictive and prognostic significance in older women 
with primary breast cancer (13). 
Furthermore, it is recognized that there are other factors which influence treatment decision making in older 
compared to younger women, such as impact of treatment on quality of life and preservation of independ-
ence (14, 15). Whilst younger women may consider curative intent the end goal of breast cancer treatment, 
older women may not be willing to tolerate the same level of invasive treatment if it means a reduction in 
their usual functioning, especially giving the slow growing nature of breast cancer in this age group.  
 
Nottingham Breast Cancer Research Programme  
The Nottingham team based in the United Kingdom has a dedicated research programme focused on pri-
mary operable breast cancer in older women. The centre describes a large consecutive series of older women 
with primary breast cancer, for whom long-term follow-up data is available (11, 16). There is also a younger 
cohort of primary breast cancer patients, available for comparative analysis (17). There are currently two 
arms of the research programme in older women, one focussing on profiling the unique biology of primary 
breast cancer in this series and the second arm, focussing on the application of geriatric assessment (GA).  
Biology theme 
The cohort consists of 1,758 women with early operable breast cancer aged 70 years. Long-term follow-up 
data (up to 37 years) and survival outcomes for the whole cohort has been collected and described (18) for 
all patients, where available. From the whole series, 813 patients underwent primary surgery. It has been 
possible to construct 575 tissue microarrays (TMAs) using the surgical excision (SE) samples and a panel of 
25 biomarkers has been assessed in these SE TMAs (11). It has been possible to construct 693 TMAs from 
CNB samples from the overall cohort. A panel of 18 biomarkers has been measured in the CNB TMAs in 
patients who had ER-positive breast cancer (19).  
Summary of significant findings to date 
Cluster analysis in both the SE TMAs and CNB TMAs identified a novel biological cluster of disease, which 
is distinct from standard clusters seen in younger women (11, 19). The unique cluster, termed ‘low ER lu-
minal’ had high expression of luminal cytokeratins, mucin (MUC)1 and HER3 compared to the other con-
ventional clusters and had different BCSS compared to conventional clusters. Similar findings suggesting a 
differing biology (with differing clinical outcomes) according to age, have also been found in terms of histo-
logical type (20), as well as in HER2-positive (21) and TNBC (22) and in response to treatment (23). Both the 
work in the SE and CNB TMAs have identified potential biomarkers which may be of use in predicting 
response to therapy and overall survival in older women with primary breast cancer.  
Geriatric assessment theme 
A prospective pilot study implementing a cancer-specific GA in older patients with primary breast cancer is 
in progress and is currently being conducted in four centres internationally. Patient recruitment commenced 
in 2009 and invites women aged ≥70 years with early-stage operable primary breast cancer to participate. 
The aim is to examine the value of using a validated cancer-specific comprehensive geriatric assessment 
(CGA) (24) to assess older patients undergoing surgery versus non-operative treatment. The CGA is per-
formed within 6-weeks and 6-months post-diagnosis, supplemented by using EORTC QLQ C-30 and BR23 
as formal measures of QOL (25, 26).  
 
Summary of significant findings to date 
A pilot study performed in Nottingham specifically examined feasibility of implementation of GA in 47 older 
women (≥70 years) with early operable primary breast cancer (27). Decision of primary treatment followed 
consultation with the clinical team and was not guided by GA. GA determined that increasing age, greater 
 
LMRJ Volume 3 Issue 3                                                                        51 | P a g e  
 
comorbidity, greater number of daily medications and slower timed up and go (a measure of physical func-
tion) were significantly related to non-surgical treatment. Quality of life remained stable at 6 months in all 
patients regardless of treatment. Average time to complete the GA was 32 minutes (range 15 – 65 minutes) 
and was conducted by a variety of trained research team members, who were not necessarily clinicians; this 
pilot study confirmed the feasibility of GA in a research setting.  
The most recent findings of the study data from three UK centres, was presented at the International Society 
of Geriatric Oncology (SIOG) 2019 annual conference and reported results from 88 women who underwent 
surgery (28). Results were conflicting in that there was an improvement in some questions related to func-
tional status and a decline in others, with no clear pattern and no relationship with intensity of surgery.  
 
The study is currently ongoing and involves several centres across the UK and Hong Kong, with the aim of 
recruiting over 1000 patients.  
 
Summary – future of the research programme 
In the future we see the development of a tool to analyse an extensive panel of biomarkers for each individual 
older women with primary breast cancer, based on their core needle biopsy specimen. This would help to 
generate a predicted outcome for each potential treatment option they are considering.  
Furthermore, development of a GA specific for primary breast cancer patients, which can be utilised along-
side the above measures of biology either in the surgical clinic or before referral at the level of general practice 
in the community, will provide a detailed understanding of individual issues which must be considered in 
discussions between healthcare professionals and patient and their families. Clear guidance needs to be de-
veloped as to how to use information derived from GA further and how to standardise potential interven-
tions. 
Effective utilisation of the unique biology and geriatric needs of older women with primary breast cancer 
will result in optimal treatment and quality of life outcomes for these patients and will provide a truly per-
sonalised approach.    
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